

10/525532

Internat' --- Application No PCT/up 33/03720

CLASSIFICATION OF SUBJECT MATTER
PC 7 A61K31/519 A61P25/06 A61P25/16 A61P25/30 A61P43/00 According to International Patent Classification (IPC) or to both national classification and IPC **B. FIELDS SEARCHED** Minimum documentation searched (classification system followed by classification symbols) IPC 7 A61K Documentation searched other than minimum documentation to the extent that such documents are included in the fleids searched Electronic data base consulted during the International search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE, EMBASE, CHEM ABS Data C. DOCUMENTS CONSIDERED TO BE RELEVANT Category ° Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. EP 0 150 469 A (MITSUBISHI CHEM IND) 1-15 7 August 1985 (1985-08-07) cited in the application table 1-3; page 19 Υ EGUCHI JUNICHI ET AL: "Effects of MCI-225 1 - 15on Memory and glucose utilization in basal forebrain-lesioned rats" PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, vol. 51, no. 4, 1995, pages 935-939, XP002257547 ISSN: 0091-3057 page 938-939, paragraph entitled "Discussion" Further documents are listed in the continuation of box C. Patent family members are listed in annex. X Special categories of cited documents: *T* later document published after the International filling date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the "A" document defining the general state of the art which is not considered to be of particular relevance invention "E" earlier document but published on or after the international *X* document of particular retevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such docu-*O* document referring to an oral disclosure, use, exhibition or ments, such combination being obvious to a person skilled in the art. document published prior to the International filing date but later than the priority date claimed "&" document member of the same patent family Date of the actual completion of the international search Date of mailing of the international search report 13 October 2003 10/11/2003 Authorized officer Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016 Borst, M

Internat' -- Application No

		PCT/uu 03/03720							
C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT Category Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. Y EGUCHI J ET AL: "The anxiolytic-like 1-15									
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.							
Υ	EGUCHI J ET AL: "The anxiolytic-like effect of MCI-225, a selective NA reuptake inhibitor with 5-HT3 receptor antagonism" PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, ELSEVIER, US, vol. 68, no. 4, April 2001 (2001-04), pages 677-683, XP002239887 ISSN: 0091-3057 page 681-682, paragraph entitled "4. Discussion"	1-15							
Υ	RAO S G: "THE NEUROPHARMACOLOGY OF CENTRALLY-ACTING ANALGESIC MEDICATIONS IN FIBROMYALGIA" RHEUMATIC DISEASES CLINICS OF NORTH AMERICA, W.B. SAUNDERS, PHILADELPHIA, PA, US, vol. 28, no. 2, 2002, pages 235-259, XP009005801 ISSN: 0889-857X page 246, last full paragraph	1-15							
Υ	WO 00 15223 A (IYENGAR SMRITI ;LILLY CO ELI (US); GOLDSTEIN DAVID JOEL (US); SIMM) 23 March 2000 (2000-03-23) page 1, line 17-19; claim 4	1-15							
Υ	WO 02 060427 A (SEPRACOR INC) 8 August 2002 (2002-08-08) page 1, line 7-20; page 7, line 16-26; page 11, line 10-13; page 14, line 11-17	1-15							
Υ	WO 02 064543 A (WYETH) 22 August 2002 (2002-08-22) page 11-17; claim 43, 47	1-15							
Y	HEAL D J ET AL: "SIBUTRAMINE: A NOVEL ANTI-OBESTIY DRUG. A REVIEW OF THE PHARMACOLOGICAL EVIDENCE TO DIFFERENTIATE IT FROM D-AMPHETAMINE AND D-FENFLURAMINE" INTERNATIONAL JOURNAL OF OBESITY, NEWMAN PUBLISHING, LONDON, GB, vol. 22, no. SUPPL 1, August 1998 (1998-08), pages S18-S28, XP008005119 ISSN: 0307-0565 page S26-S27, paragraph entitled "Summary"	1-15							
Υ	WO 96 12485 A (LILLY CO ELI) 2 May 1996 (1996-05-02) page 1, line 17-20, claim 1-3	1-15							

Inte nal application No.

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This International Searching Authority found multiple Inventions in this international application, as follows:
see additional sheet
·
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. X As all searchable daims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1,5,7,14,15(part)

Use of MCI 225 or a salt thereof for the treatment of fibromyalgia, premenstrual syndrome, migraine, fatigue

2. Claims: 2,6,10,11,15(part)

Use of MCI 225 or a salt thereof for the treatment of obesity/weight gain, eating disorders, nausea/vomiting, chemotherapy/radiation induces emesis

3. Claims: 3,4,15(part)

Use of MCI 225 or a salt thereof for the treatment of substance abuse/drug addiction, smoking cessation

4. Claims: 8,9,12,13,15(part)

Use of MCI 225 or a salt thereof for the treatment of Parkinson's disease, stroke, schizophrenia, obsessive compulsive disorders

ation on patent family members

Internati 1 Application No

Patent document cited in search report		Publication date	-	Patent family member(s)		Publication date
EP 0150469	Α,	07-08-1985	JP	1699365 0	1 }	28-09-1992
			JP	3067071 E		21-10-1991
			JP	60146891 A		02-08-1985
			ΑT	35137 T		15-07-1988
			CA	1224782 A	۱1	28-07-1987
			DE	3472106 [)1	21-07-1988
			DK	617184 A	A ,B,	06-07-1985
			EP	0150469 A	۱۱ ۱	07-08-1985
			HU	37435 A	12	28-12-1985
			US	4695568 A	4	22-09-1987
WO 0015223	A	23-03-2000	AU	746887 E	32	02-05-2002
			AU	1197200 A	4	03-04-2000
			BR	9913671 A		05-06-2001
			CA	2344057 A		23-03-2000
			CN	1316904 7		10-10-2001
			EP	1113797 <i>A</i>		11-07-2001
			JP	2002524513		06-08-2002
			MO	0015223 A		23-03-2000
			US	6596756 E	31 	22-07-2003
WO 02060427	Α	08-08-2002	US	2002006964 A		17-01-2002
			WO	02060427 A		08-08-2002
			US	2003078303 A	\1	24-04-2003
WO 02064543	 А	22-08-2002	WO	02064543 A	12	22-08-2002
			US	2003045583 A	A1	06-03-2003
WO 9612485	 А	02-05-1996	AU	4131296 <i>A</i>	<i>-</i>	15-05-1996
			WO	9612485 A		02-05-1996
			ZA	9508725 A	3	16-04-1997